Navigation Links
New Study Confirms Role for Pertussis Immunization of Entire Family,in Reducing Infant Pertussis

smit pertussis to infants and that pertussis immunization of adolescents and adults would not only have an effect on their own health, but would also protect young infants from pertussis," said Dr. Van Rie. "Those who have an infant at home or who come into contact with infants at work should be immunized against pertussis."

About Adacel Vaccine

Adacel vaccine is the first booster to address pertussis protection across a wide range of ages (11 through 64 years) and the first and only booster licensed for adults in the United States. It was licensed by the U.S. Food and Drug Administration (FDA) on June 10, 2005. Adacel vaccine is administered as a single, 0.5mL dose by intramuscular injection. It is similar to DAPTACEL(R) (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed), a diphtheria, tetanus, and pertussis vaccine used to protect infants and young children because it is also based on sanofi pasteur's 5-antigen pertussis vaccine. In clinical studies, DAPTACEL vaccine has been shown to provide 85 percent efficacy against severe pertussis (cough lasting 21 days or longer) and 78 percent efficacy against all severities of pertussis.

Important Safety Information

There are risks associated with all vaccines. The most common injection site adverse events include pain, erythema, and swelling. The most common systemic adverse events include headache, body ache, tiredness, and fever. Adacel vaccine is contraindicated in persons with known systemic hypersensitivity to any component of the vaccine or a life-threatening reaction after previous administration of the vaccine or a vaccine containing the same substances. Because of uncertainty as to which component of the vaccine may be responsible, no further vaccination with the diphtheria, tetanus, or pertussis components found in Adacel vaccine should be carried out. Because any intramuscular injection can cause injection site hematoma, Adacel vaccine should not be given to p
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/21/2014)... , July 21, 2014 Decision Resources ... (AD) therapies will more than triple, reaching nearly ... forecasted launch of the first disease-modifying therapies (DMTs), ... these novel premium-priced agents—which include the anti-beta-amyloid monoclonal ... well as the BACE inhibitor MK-8931 (Roche/Chugai/MorphoSys)—will earn ...
(Date:7/21/2014)... ALBANY, New York , July 21, 2014 /PRNewswire/ ... market report published by Transparency Market Research "E-Clinical Solution ... and Forecast, 2014 - 2020," the global microfluidic device ... and is expected to grow at a CAGR of ... value of USD 6,515.3 million in 2020. ...
(Date:7/21/2014)...  PowerVision, Inc., a medical device company developing ... announced that Douglas D. Koch , M.D., ... and Professor of Ophthalmology, at Baylor College of ... As a recipient of several ... Lifetime Achievement award, Koch will join the distinguished ...
Breaking Medicine Technology:The Alzheimer's Disease Market Is Forecast to Reach Nearly $12 Billion by 2023, Following the Projected Launch of the First Disease-Modifying Therapies 2The Alzheimer's Disease Market Is Forecast to Reach Nearly $12 Billion by 2023, Following the Projected Launch of the First Disease-Modifying Therapies 3E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 3E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 4E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 5PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4
... 13, 2011  GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based ... fight Human Immunodeficiency Virus (HIV) infections, announced that the ... clinical trial for the Company,s HIV/AIDS therapeutic vaccine.  This ... the treatment of persons who are HIV infected. ...
... Masimo (NASDAQ: MASI ) ... Acoustic Respiration Rate (RRa™) was presented at the ... Graduate Assembly (PGA) Meeting in New York City. ... the positive clinical outcomes and patient safety impact of Masimo,s ...
Cached Medicine Technology:GeoVax Labs' First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine 2GeoVax Labs' First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine 3New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 2New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 3New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 4New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 5
(Date:7/22/2014)... Hope For The Warriors® is excited to ... staff. This addition comes in tandem with new office ... The Warriors® is a national nonprofit organization that assists ... the fallen who have sustained physical and psychological wounds ... will support programs within Career Transition & Education. He ...
(Date:7/22/2014)... Garland’s new Energizer BK ... used as a flood coat over new and existing ... premium restoration material. It provides natural resistance to moisture, ... reducing life-cycle costs. Energizer BK is specially formulated with ... resistance in addition to superior strength and flexibility. ...
(Date:7/22/2014)... July 22, 2014 The hair ... are now offering robotic assisted laser therapy and ... solutions for men and women suffering from hair ... they now offer Follicular Unit Extraction (FUE) procedures ... robot. With this new technology, their doctors use ...
(Date:7/21/2014)... fastest-growing high school sports in the United States, with ... game. The growing participation numbers, however, mean that more ... in lacrosse practice and competition. , In a study ... Sports Medicine and available in an upcoming print ... Policy at Nationwide Children,s Hospital and the Colorado School ...
(Date:7/21/2014)... As reported by CBS Local Pittsburgh in the article ... (7/15), thrill-seeking participants raised $100,000 to raise drug abuse ... Philly. 100 people, including some well-known local news reporters, ... Hotel. Some of the participants shared stories of their ... son killed himself after a long battle with addiction. ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Builds on Staff and Office Space in Chicago to Support Career Transition for Vets 2Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 3Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 2Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 3
... --MinuteClinic Provides Quality and Convenience Close to Home and the ... ... Alliance With Integris Health--, OKLAHOMA CITY, Sept. 7 Quick, convenient, ... opening of a,MinuteClinic health care center at the CVS/pharmacy store in Moore ...
... pulmonary embolisma potential life-threatening blockage in a lung arteryshould ... than a CT (computed tomography) angiogram, conclude authors in ... Medicine. , A V/Q scan can be the first ... a pulmonary embolism, noted H. Dirk Sostman, a professor ...
... School at the University of Warwick reveals that womens health ... , The researchers looked at men and women sleeping ... see if their risk of having hypertension was any higher ... more of sleep a night. Among other problems increased hypertension ...
... Blue Shield in Indiana for its Members, INDIANAPOLIS, ... and,M-Plan, Inc., an Indiana-based managed care organization, announced today,that ... of Indiana as,the insurer of choice for its members ... WellPoint and M-Plan have entered into an,agreement that ensures ...
... KING OF PRUSSIA, PA, Sept. 7 /PRNewswire-FirstCall/ - ... discovery and development,solutions, has won the Good Clinical ... that best promotes access to new medicines. This,award ... awards introduced this year to,recognize excellence in clinical ...
... N.J., Sept. 6 Wyeth (NYSE: WYE ... that the United States,District Court for the District ... a preliminary injunction against Teva Pharmaceuticals USA, Inc.,and ... of a generic,version of PROTONIX(R) (pantoprazole sodium) prior ...
Cached Medicine News:Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 2Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 3Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 4Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 5Health News:Nuclear medicine approach can be first choice for excluding pulmonary embolism in young women 2Health News:WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana 2Health News:WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana 3Health News:MDS Pharma Services Wins Award for Management of Global Malaria Trial 2Health News:Wyeth and Nycomed Announce Court Denial of Preliminary Injunction 2Health News:Wyeth and Nycomed Announce Court Denial of Preliminary Injunction 3
... At the heart of the innovative ... EU-M60, delivering excellent imaging performance to meet ... Together with the new GF-UM160 ultrasonic gastrovideoscope, ... penetration to view organs deeper in the ...
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Ultrasensitive TSH EIA Thyroid Function 025-BC-1003...
Total T3 EIA Thyroid Function 025-BC-1005...
Medicine Products: